Your browser doesn't support javascript.
loading
Neutralizing antibodies after the third COVID-19 vaccination in healthcare workers with or without breakthrough infection.
Reinholm, Arttu; Maljanen, Sari; Jalkanen, Pinja; Altan, Eda; Tauriainen, Sisko; Belik, Milja; Skön, Marika; Haveri, Anu; Österlund, Pamela; Iakubovskaia, Alina; Pasternack, Arja; Naves, Rauno A; Ritvos, Olli; Miettinen, Simo; K Häkkinen, Hanni; Ivaska, Lauri; Tähtinen, Paula A; Lempainen, Johanna; Kantele, Anu; Kakkola, Laura; Julkunen, Ilkka; Kolehmainen, Pekka.
Afiliação
  • Reinholm A; Institute of Biomedicine, University of Turku, Turku, Finland. arttu.j.reinholm@utu.fi.
  • Maljanen S; Institute of Biomedicine, University of Turku, Turku, Finland.
  • Jalkanen P; Institute of Biomedicine, University of Turku, Turku, Finland.
  • Altan E; Institute of Biomedicine, University of Turku, Turku, Finland.
  • Tauriainen S; Institute of Biomedicine, University of Turku, Turku, Finland.
  • Belik M; Institute of Biomedicine, University of Turku, Turku, Finland.
  • Skön M; Finnish Institute for Health and Welfare, Helsinki, Finland.
  • Haveri A; Finnish Institute for Health and Welfare, Helsinki, Finland.
  • Österlund P; Finnish Institute for Health and Welfare, Helsinki, Finland.
  • Iakubovskaia A; Department of Physiology, Medicum, University of Helsinki, Helsinki, Finland.
  • Pasternack A; Department of Physiology, Medicum, University of Helsinki, Helsinki, Finland.
  • Naves RA; Department of Physiology, Medicum, University of Helsinki, Helsinki, Finland.
  • Ritvos O; Department of Physiology, Medicum, University of Helsinki, Helsinki, Finland.
  • Miettinen S; Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki, University Hospital and University of Helsinki, Helsinki, Finland.
  • K Häkkinen H; Department of Virology, University of Helsinki, Helsinki, Finland.
  • Ivaska L; Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland.
  • Tähtinen PA; InFlames Research Flagship Center, University of Turku, Turku, Finland.
  • Lempainen J; Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland.
  • Kantele A; Institute of Biomedicine, University of Turku, Turku, Finland.
  • Kakkola L; Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland.
  • Julkunen I; Clinical Microbiology, Turku University Hospital, Turku, Finland.
  • Kolehmainen P; Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki, University Hospital and University of Helsinki, Helsinki, Finland.
Commun Med (Lond) ; 4(1): 28, 2024 Feb 23.
Article em En | MEDLINE | ID: mdl-38396065
ABSTRACT

BACKGROUND:

Vaccinations against the SARS-CoV-2 are still crucial in combating the ongoing pandemic that has caused more than 700 million infections and claimed almost 7 million lives in the past four years. Omicron (B.1.1.529) variants have incurred mutations that challenge the protection against infection and severe disease by the current vaccines, potentially compromising vaccination efforts.

METHODS:

We analyzed serum samples taken up to 9 months post third dose from 432 healthcare workers. Enzyme-linked immunosorbent assays (ELISA) and microneutralization tests (MNT) were used to assess the prevalence of vaccine-induced neutralizing antibodies against various SARS-CoV-2 Omicron variants.

RESULTS:

In this serological analysis we show that SARS-CoV-2 vaccine combinations of BNT162b2, mRNA-1273, and ChAdOx1 mount SARS-CoV-2 binding and neutralizing antibodies with similar kinetics, but with differing neutralization capabilities. The most recent Omicron variants, BQ.1.1 and XBB.1.5, show a significant increase in the ability to escape vaccine and infection-induced antibody responses. Breakthrough infections in thrice vaccinated adults were seen in over 50% of the vaccinees, resulting in a stronger antibody response than without infection.

CONCLUSIONS:

Different three-dose vaccine combinations seem to induce considerable levels of neutralizing antibodies against most SARS-CoV-2 variants. However, the ability of the newer variants BQ1.1 and XBB 1.5 to escape vaccine-induced neutralizing antibody responses underlines the importance of updating vaccines as new variants emerge.
During the COVID-19 pandemic, mass vaccination efforts against SARS-CoV-2 infection have provided effective protection against the virus and helped reduce the severity of symptoms in infected individuals. However, it is not well established whether the existing vaccines can provide the same protection against new and emerging SARS-CoV-2 variants that develop over time as the virus evolves. In this study, we tested combinations of three-dose COVID-19 vaccines given in random order to protect against all SARS-CoV-2 variants in circulation including the newest being Omicron variants. We demonstrate that more than half of the population who received the three-dose vaccine combinations were infected with SARS-CoV-2 Omicron variants after receiving the last vaccine dose. These findings indicate the need to develop new vaccine candidates against emerging SARS-CoV-2 variants.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article